Business & Development
-
ShoreCap stays at ‘buy’ on Bunzl, says prospects look assured
Analysts at ShoreCap stood by their ‘buy’ recommendation on shares of Bunzl, pointing out the company’s revised guidance for margins. That was…
-
Broker tips: GSK, IHG, 888
Citigroup put pharmaceuticals company GlaxoSmithKline on “positive catalyst watch” on Friday as it pointed to legal developments related to the company’s now-discontinued…
-
Citi puts GSK on ‘positive catalyst watch’, cites Zantac litigation developments
Citigroup put pharmaceuticals company GlaxoSmithKline on “positive catalyst watch” on Friday as it pointed to legal developments related to the company’s now-discontinued…
-
Citi puts GSK on ‘positive catalyst watch’, cites Zantac ligation developments
Citigroup put pharmaceuticals company GlaxoSmithKline on “positive catalyst watch” on Friday as it pointed to legal developments related to the company’s now-discontinued…
-
Deutsche Bank downgrades Europe stocks to ‘neutral’, point to slowing growth in China and Europe
Equity strategists at Deutsche Bank downgraded their view on European equities to ‘neutral’ after the Euro Stoxx 50 moved slightly above their…
-
Berenberg cuts 888 price target, reiterates ‘buy’ rating
Berenberg cut its price target on 888 Holdings on Friday to 320p from 370p as it reduced estimates following weaker-than-expected revenue guidance,…
-
JPM downgrades IHG to ‘neutral’, reiterates ‘overweight’ on Whitbread
JPMorgan Cazenove downgraded InterContinental Hotels Group on Friday but reiterated its ‘overweight’ rating on Premier Inn owner Whitbread as it took a…
-
Micro Focus agrees to £5bn takeover by Canada’s OpenText
Software maker Micro Focus said it had agreed a £5.1bn takeover, including debt, by Canadian rival OpenText. The offering is £5.32 per…
-
Broker tips: Hargreaves Lansdown, Biffa, AstraZeneca
Analysts at JP Morgan reiterated their underweight stance on Hargreaves Lansdown due to the combination of their forecasts for a drop in…
-
ShoreCap stays at ‘buy’ for Astra Zeneca, citing prospects for earnings and sales growth, pipeline
Analysts at ShoreCap doubled down on their recent reinitiation of coverage on AstraZeneca with a ‘buy’ recommendation, citing growth and pipeline prospects.…
Wealth DFM Talk is our flagship podcast, that fits perfectly into your busy life, bringing the latest insight, analysis, news and interviews to you, wherever you are.
Wealth DFM Talk Podcast – listen to the latest episode
